Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM-101 + nivolumab in advanced melanoma
NCT03711188Phase 2Completed
- Sponsor
- Immodulon Therapeutics
- Start
- Oct 2018
- Primary completion
- Dec 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of IMM-101 in melanoma, sponsored by Immodulon Therapeutics. Primary endpoints: Safety and Tolerability of the Combination of IMM-101 + Nivolumab up to 84 weeks and Overall Response Rate at 18 months. Started Oct 2018; status: completed.
02
Drugs
IMM-101
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03711188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03711188.